Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with advanced breast cancer: A systematic review and network meta-analysis

Researchers performed a systemic review of data from PubMed and Cochrane Library to evaluate the incidence of major adverse cardiovascular events and hypertension associated with the use of CDK4/6 inhibitors among patients with advanced breast cancer. They found that in this patient population, abemaciclib plus endocrine therapy may have a lower risk of major adverse cardiovascular events, whereas palbociclib plus endocrine therapy may reduce the risk of hypertension.